Pulmonary Surfactants (Pulmonary Surfactant)

08/01/2008 - "[Combined use of pulmonary surfactants with continuous distending pressure is useful in the treatment of respiratory distress syndrome in very low birth weight infants]."
04/01/2018 - "Gender-related efficacy of pulmonary surfactant in infants with respiratory distress syndrome: A STROBE compliant study."
01/01/2023 - "The comparative efficacy of pulmonary surfactant in the treatment of respiratory distress syndrome in preterm infants remains unclear. "
01/01/2023 - "Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis."
03/01/2014 - "To evaluate the efficacy of calf pulmonary surfactant (PS) in the treatment of respiratory distress syndrome (RDS) in late preterm and full-term infants. "

08/12/2022 - "To investigate the efficacy of high-frequency oscillatory ventilation (HFOV) combined with pulmonary surfactant (PS) in the treatment of neonatal respiratory distress syndrome (NRDS). "
04/01/1989 - "Pulmonary surfactant replacement has previously been shown to be effective in the human neonatal respiratory distress syndrome. "
05/02/2020 - "[Efficacy of minimally invasive pulmonary surfactant administration in preterm infants with neonatal respiratory distress syndrome: a multicenter clinical trial]."
04/01/2012 - "[Comparisons of efficacy of different pulmonary surfactants for the treatment of neonatal respiratory distress syndrome]."
11/25/2020 - "Pulmonary surfactant (PS) is commonly used for the treatment of neonatal respiratory distress syndrome (NRDS), several randomized controlled trials (RCTs) have evaluated the role of nebulized versus invasively delivered PS, yet the results remained inconsistent. "

01/01/2017 - "Acute lung injury in the preterm newborns can originate from prematurity of the lung and insufficient synthesis of pulmonary surfactant. "
06/01/2016 - "The effect of matrix metalloproteinase-3 deficiency on pulmonary surfactant in a mouse model of acute lung injury."
09/01/2015 - "Degeneration of pulmonary surfactant is the essential cause of acute lung injury (ALI). "
01/01/2013 - "Anti-inflammatory treatment in dysfunction of pulmonary surfactant in meconium-induced acute lung injury."
03/01/2012 - "[Effects of pulmonary surfactant in treatment of acute lung injury after cardiac surgery in infants]."

10/01/2008 - "These data suggest that pulmonary surfactant and its synthetic compound are safe and effective mucosal adjuvants that enhance the protective immunity without incurring a risk of inflammation."
12/01/2021 - "After 6 h, livers and lungs were analyzed for inflammation and, additionally, the amounts and function of pulmonary surfactant were measured. "
01/01/2021 - "Pulmonary surfactants are vital in the lungs to reduce the surface tension and inflammation. "
01/01/2021 - "SARS-CoV-2 also destroys the type II alveolar cells that secrete pulmonary surfactants, which normally decrease the air/tissue surface tension and block TLR4 in the lungs thus promoting ARDS and inflammation. "
01/01/2021 - "Shared processes included upregulation of inflammation, response to oxidative stress, and the loss of pulmonary surfactant. "

05/01/2007 - "The development of neonatology and the availability of pulmonary surfactant have been helpful in effective reduction of the mortality of very low birth weight infants at the expense of an increasing number of survivors with bronchopulmonary dysplasia (BPD) caused by lung immaturity. "
01/01/2018 - "This study aimed to correlate the pulmonary surfactant B (SP-B) gene variation with bronchopulmonary dysplasia (BPD) in ethnic Han, Chinese, premature newborns. "
01/01/2022 - "The measurements related to early respiratory support effect before cord clamping including positive end-expiratory pressure (PEEP) and FiO2 during transition/leaving the delivery room, intubation rate during transition, pulmonary surfactant (PS) administration ≥2 times after birth, extubation failure, and incidence of bronchopulmonary dysplasia (BPD) were collected as the secondary outcomes. "
09/15/2001 - "With advent of the availability of pulmonary surfactants, the prevalence of wheezing at age 8 decreased from 50% to 16% (p = 0.002) among children with bronchopulmonary dysplasia, but it increased from 14% to 38% among those with milder neonatal respiratory disease. "
09/01/1990 - "Because of substantial clinical and laboratory evidence of the efficacy of glucocorticoids in the treatment of acute pulmonary surfactant deficiency in preterm newborns, we explored the hypothesis that maternal antenatal glucocorticoid receipt is followed by reduced risk of bronchopulmonary dysplasia (BPD). "